Maral Root for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Rhaponticum carthamoides, Leuzea carthamoides, Stemmacantha carthamoides, Russian Leuzea, Leuzea, Maralroot, Maral Root Extract

Motivation

Maral root is the underground part of a hardy mountain plant from southern Siberia, sold as a powder or concentrated extract. It is prized for one family of plant compounds it carries in unusually high amounts — insect-type steroids that plants make to deter grazing insects. In people these compounds do not act on the same target as testosterone, so the root is promoted as muscle and stamina support without the hormonal side effects of anabolic drugs.

Herders in the Altai and Sayan mountains used the root to restore strength after illness, and Soviet scientists studied it for decades as a tonic for soldiers and athletes. Much of that work was never published in English, so the plant reached Western shelves with a large reputation and a thin public record. Anti-doping authorities now track its main compound.

This review examines what is known about maral root: how its compounds are thought to work, what human and animal studies report for muscle, metabolism and ageing, which harms and product-quality problems have been documented, and how it is typically dosed and monitored.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

This section collects high-level overviews of maral root and its principal constituent from sources that discuss them in substantial depth.

• Chemistry and pharmacology of Rhaponticum carthamoides: a review - Kokoska & Janovska, 2009

  The single most complete English-language account of the plant, built from 117 sources, most originally Russian, covering traditional use, 120 isolated compounds, pharmacology and toxicity.

• Maral Root Extract and Its Main Constituent 20-Hydroxyecdysone Enhance Stress Resilience in Caenorhabditis elegans - Todorova et al., 2025

  The only study to test whole maral root extract against lifespan and healthspan endpoints, with validated quantification of the three phytoecdysteroids actually present in the extract used.

• Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans - Isenmann et al., 2019

  The pivotal human training study of ecdysterone, maral root’s main plant steroid, and the paper that triggered anti-doping interest; most current claims about the root trace back to it.

• Ecdysterone: Results, Side Effects & Research - Christian Finn

  A sceptical, well-sourced appraisal of ecdysterone, the plant steroid maral root is standardised for, walking through the positive and null human trials and their design weaknesses.

• Ecdysterone and Turkesterone Dietary Supplements - Operation Supplement Safety

  Concise regulatory and safety orientation on ecdysterone, maral root’s main plant steroid, from the US military supplement-safety programme: monitoring status, labelling accuracy, contamination and a referenced bottom line.

The only priority-platform coverage located is a brief ecdysteroid segment inside a broader Huberman Lab hormone episode, which does not treat this topic in depth, so the list draws on the wider literature.

Grokipedia

• Rhaponticum carthamoides

  Traces the plant’s name to Siberian folklore about the maral deer and assembles botany, phytochemistry and pharmacology in one place, with more Russian-source detail than most English references.

Examine

• Maral Root benefits, dosage, and side effects

  States plainly that applied human studies are absent and highlights the rapid serum clearance of 20-hydroxyecdysone as the central obstacle to oral efficacy — the key counter-argument to marketing claims.

ConsumerLab

No ConsumerLab article, product review, recall or clinical update exists for maral root, Rhaponticum carthamoides or ecdysterone. ConsumerLab has not tested this supplement category.

Systematic Reviews

This section lists the systematic reviews that pool the published work on maral root and its plant genus.

• Rhaponticum genus: a systematic review on traditional uses, phytochemical profiles and pharmacological activities - Wurentuya et al., 2026

  Collates 217 compounds and the pharmacological record across the genus, including Rhaponticum carthamoides, and flags missing toxicology data.

• Comparison between the Biological Active Compounds in Plants with Adaptogenic Properties (Rhaponticum carthamoides, Lepidium meyenii, Eleutherococcus senticosus and Panax ginseng) - Todorova et al., 2021

  Screens 259 papers under systematic-review reporting standards to catalogue maral root’s constituents alongside three better-studied adaptogens.

• Plant Adaptogens-History and Future Perspectives - Todorova et al., 2021

  Pools the limited clinical trial evidence on plant adaptogens including Rhaponticum carthamoides, covering fatigue, cognitive impairment and immune protection.

All three reviews cover the claimed-benefit side; no systematic review or meta-analysis covers product-quality failure or long-term safety, so that half of the trade-off is unrepresented.

Mechanism of Action

Maral root’s activity is attributed mainly to phytoecdysteroids (plant-made steroids that mimic insect moulting hormones), of which 20-hydroxyecdysone (20E, sold as ecdysterone) dominates. Dried roots contain roughly 0.05–1.74% 20E alongside about fifty minor ecdysteroids, caffeoylquinic acids and flavonoids (Todorova et al., 2024).

20E does not bind the androgen receptor. Cell and rodent work points instead to estrogen receptor beta (ER-β, a receptor subtype abundant in skeletal muscle): ecdysterone enlarges muscle fibres, and an ER-β blocker abolishes the effect (Parr et al., 2014). A second proposed route is the Mas receptor of the renin–angiotensin system (the hormone network controlling blood pressure and fluid balance); both converge on PI3K/Akt/mTOR (a signalling cascade that switches on muscle protein synthesis). The root’s polyphenols act separately, raising SIRT6 and Nrf2 (proteins governing energy metabolism and antioxidant defence) and damping NF-κB (a master switch for inflammation) (Zheng et al., 2022).

A competing explanation holds that little 20E reaches muscle: human dosing by Biophytis, the company developing a purified version commercially, gives a short half-life of 2.4–4.9 hours, less-than-proportional exposure as dose rises, extensive conversion to 14-deoxy metabolites, and renal clearance of 4–5 L/h (Dioh et al., 2023). On this view the polyphenol fraction, not the ecdysteroids, carries most of the effect. Selectivity is low, tissue distribution broad, and no cytochrome P450 (the liver’s main drug-metabolising enzyme family) interactions have been characterised.

Historical Context & Evolution

Maral root takes its name from the Siberian maral deer, said to dig for the rhizomes during the rut. Altai and Sayan herders used a decoction to restore strength after illness, for weakness in old age and for male sexual complaints (Kokoska & Janovska, 2009).

Systematic study began in the Soviet Union in the 1940s. Pharmacologists reported that alcoholic root extracts stimulated the central nervous system and improved learning and retention in rats (Petkov et al., 1984), and in 1969 Brekhman & Dardymov placed the plant in their newly proposed adaptogen category — agents said to raise non-specific resistance to physical and psychological strain. A purified 20-hydroxyecdysone tablet was later registered as a medicine in the Soviet sphere, and the root remains a monograph entry in the Russian Pharmacopoeia (Shikov et al., 2021). Soviet sports institutes used it with weightlifters and endurance athletes; most of that data appeared only in Russian and is hard to appraise today, which is a reason for caution but not a reason to treat it as refuted.

Interest moved west in the 1990s through the sports-supplement trade, largely on the strength of those untranslated claims rather than new work. Two developments reopened the file: a 2019 German training study reporting measurable strength gains (Isenmann et al., 2019), and pharmaceutical development of purified 20-hydroxyecdysone for age-related muscle loss. Neither settles the older claims; both shifted attention from the whole root to its main constituent, leaving the crude extract still thinly studied.

Expected Benefits

Medium 🟩 🟩

Muscle Hypertrophy and Maximal Strength During Resistance Training ⚠️ Conflicted

In a 10-week controlled study, 46 strength-training men taking an ecdysterone product gained more muscle mass and more bench-press strength than placebo, with no change in the urinary steroid profile (Isenmann et al., 2019). An earlier 8-week randomised trial giving 200 mg of 20-hydroxyecdysone daily found no effect on lean mass or maximal strength (Wilborn et al., 2006). Body composition in the positive study was measured by bioelectrical impedance, and squat strength did not separate from placebo — both weaken the finding.

Magnitude: Roughly 1.5 kg (lower dose) and 2 kg (higher dose) of lean mass over 10 weeks versus placebo, with bench-press one-repetition maximum (1RM, the heaviest single lift) rising 11.5% and 9.5% against 3.6% for placebo; squat gains did not differ.

Low 🟩

Walking Speed and Physical Function in Age-Related Muscle Loss

A purified 20-hydroxyecdysone drug tested in 233 sarcopenic (age-related muscle loss) adults over 65 improved 400-metre walking speed in the per-protocol analysis (those who completed treatment as planned) but not across everyone randomised (Fielding et al., 2025); sponsor Biophytis funded it. Evidence applies to the isolated constituent, not root extract.

Magnitude: 0.09 m/s faster 400-metre gait speed versus placebo in the per-protocol population and 0.07 m/s across everyone randomised, against a 0.1 m/s threshold usually treated as clinically meaningful.

Glucose Control and Blood Lipid Profile

In rats fed a high-fat diet for eight weeks, root extract lowered fasting glucose and improved glucose tolerance and dyslipidaemia (abnormal blood fats) more than liquorice or pomegranate extracts, and raised liver PPAR-α activity (a switch controlling fat burning) (Dushkin et al., 2014). No human trial has tested this.

Magnitude: Fasting glucose fell 19.4% and epididymal fat-pad weight 19.0% versus high-fat-diet controls in rats at 300 mg/kg/day; no human figure exists.

Vascular Anti-Inflammatory and Antioxidant Activity

Root extract given to diabetic mice for 12 weeks raised nitric oxide and endothelial nitric oxide synthase activity, increased SIRT6, and lowered TNF-α and interleukin-1β (inflammatory messengers) in the aorta (Nan et al., 2024). The root’s caffeoylquinic acids are strong radical scavengers in laboratory assays.

Magnitude: Direction is consistent — lower aortic TNF-α and interleukin-1β and higher nitric oxide in diabetic mice across 60–240 mg/kg — but no human study reports an outcome figure for inflammation or vascular function.

Fatigue Resistance and Physical Work Capacity ⚠️ Conflicted

Soviet-era reports and rodent work describe reduced fatigue and greater work capacity, the basis of the plant’s adaptogen label. A randomised crossover trial of a 70:30 maral root and Rhodiola rosea blend in 30 men found no effect on fatigue during repeated maximal leg extensions (Ryan et al., 2021).

Magnitude: Direction is positive in rodents but null in the only human test — single 175 mg or 350 mg doses produced no difference in torque decline or perceived exertion across five sets — and no human outcome figure supports benefit.

Learning and Memory

Aqueous-alcoholic root extract improved acquisition and retention of learned tasks in rats and stimulated the central nervous system (Petkov et al., 1984; Mosharrof, 1987). This work predates modern behavioural reporting standards and has never been repeated in people.

Magnitude: Not quantified in available studies. The rodent reports predate standardised effect-size reporting and no human trial has measured cognition after maral root intake.

Clearance of Intestinal Giardia Infection

A randomised, double-blind, placebo-controlled trial in 76 athletes infected with Giardia lamblia (a common intestinal parasite) reported complete clearance after ten days of 20-hydroxyecdysone, matching metronidazole (Toychiev et al., 2022). Single-centre and never replicated; it tests the isolated constituent, not root extract.

Magnitude: 100% elimination of Giardia lamblia in the 20-hydroxyecdysone group against 96% with metronidazole, where the remaining 4% of infections proved metronidazole-resistant.

Speculative 🟨

Healthspan and Lifespan Extension

Maral root extract and its ecdysterone extended lifespan and improved stress resistance and movement in the nematode Caenorhabditis elegans (Todorova et al., 2025). No vertebrate lifespan data exist; the basis is a single invertebrate model.

Cardioprotection Under Ischaemic Stress

Root extract limited heart-muscle injury in rats given a stress hormone, acting through SIRT6 and Nrf2 (Zheng et al., 2022). Basis is animal and mechanistic only; no human cardiac outcome has been studied.

Immune Modulation

Extracts of the root show immunomodulatory activity (shifting immune activity) in animal and laboratory studies (Kokoska & Janovska, 2009). Basis is preclinical only; no human immune outcome has been measured after maral root intake.

Support for Male Sexual Function

Siberian tradition and Soviet reports describe use for impotence, and the genus review lists reproductive and sexual-function effects (Kokoska & Janovska, 2009). No controlled study in men exists; the basis is traditional use only.

Anti-Tumour Activity in Laboratory Models

Root extract killed leukaemia and lung-tumour cells (Skała et al., 2018) and triggered programmed cell death in brain-tumour lines (Skała et al., 2018). Basis is laboratory work only; no human cancer outcome exists.

Benefit-Modifying Factors

• Estrogen receptor beta genotype: Because the muscle effect appears to run through ER-β, common variants in the ESR2 gene (which encodes ER-β) that alter receptor expression are the most plausible source of responder and non-responder differences. This has never been tested directly.

• Baseline muscle mass and training stimulus: Every positive human signal came from participants performing structured resistance training. Without a progressive training stimulus there is no mechanism for the proposed protein-synthesis effect to act on, and no benefit should be expected.

• Baseline biomarker levels: The metabolic effects in animals were seen only against a high-fat-diet background with raised glucose and lipids. Someone already at optimal fasting glucose, triglycerides and inflammatory markers has little headroom for a measurable change.

• Sex-based differences: All human ecdysterone training data come from men. An ER-β-mediated mechanism sits on a pathway with different baseline tone in women, so both the size and the direction of effect in women are untested rather than known.

• Pre-existing health conditions: Sarcopenia, obesity and type 2 diabetes are the states in which the largest signals appear, because each supplies the deficit the compound is proposed to correct. Metabolically healthy trained adults are the hardest population in which to show benefit.

• Age-related considerations: The only trial in adults over 65 found plasma exposure 13–22% lower than in young subjects at the same dose (Dioh et al., 2023), placing older users at the lower end of the exposure range that produced the clinical signal.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Ecdysteroid Content Far Below the Label Claim

Quantification of twelve commercial ecdysterone supplements found actual content generally far below the declared amount (Ambrosio et al., 2020). A 2025 randomised training study analysed its own study product and found under 1% of the claimed 20-hydroxyecdysone, with no biological activity in muscle-cell assays (Dissemond et al., 2025). The practical consequence is paying for, and dosing, an inert powder — and drawing false conclusions from a null personal trial.

Magnitude: Under 1% of the labelled 20-hydroxyecdysone in the one commercial product formally analysed inside a trial, and content generally far below label across all twelve products tested in the earlier survey.

Undeclared and Prohibited Drugs in Sports Supplements

Analysis of 57 sports supplements listing botanical ingredients with claimed stimulant or anabolic effects found frequent mislabelling and, in several products, compounds prohibited by the US Food and Drug Administration (FDA), including stimulants never approved in any country (Cohen et al., 2023). Maral root products sit in exactly this market segment. Consequences run from a failed drug test to a cardiovascular event from an undeclared stimulant.

Magnitude: 12% of 57 products contained at least one FDA-prohibited ingredient, 40% contained no detectable amount of the labelled botanical, and only 11% fell within 10% of the labelled quantity.

Medium 🟥 🟥

Doping-Control Exposure for Tested Athletes

Ecdysterone has been on the World Anti-Doping Agency (WADA, the body that sets doping rules for Olympic-movement sport) Monitoring Program since 2020, and the laboratories that studied it formally recommended moving it to the prohibited list as an anabolic agent (Isenmann et al., 2019). Those same anti-doping laboratories are funded to detect and classify such substances, so their recommendation is an interested one. Detailed metabolite mapping now makes urinary detection straightforward (Piper & Thevis, 2023).

Magnitude: Not a sanctionable finding today; direction of risk is upward if the status changes, and administration studies traced urinary metabolites across the 14 days following a single dose. No outcome figure for sanction risk exists.

Low 🟥

Central Stimulation, Restlessness and Disturbed Sleep

Alcoholic root extract produced clear central nervous system stimulation in rodents (Petkov et al., 1984). Russian practice has long treated insomnia, agitation and epilepsy as reasons to avoid leuzea. User reports describe over-stimulation with late-day dosing; the effect reverses on stopping.

Magnitude: Not quantified in available studies. No controlled trial has measured sleep quality or agitation after maral root intake, leaving only traditional contraindications and uncontrolled user reports.

Blood Pressure Elevation in Susceptible Individuals ⚠️ Conflicted

Russian monographs list arterial hypertension (persistently raised blood pressure) as a contraindication for leuzea preparations, consistent with a stimulant profile. Pharmacological work on the genus reports the opposite — antihypertensive activity (Wurentuya et al., 2026) — so the direction in humans is genuinely unresolved.

Magnitude: Direction is disputed: traditional sources warn of rises in people with existing hypertension while animal pharmacology shows falls, and no human study reports a blood-pressure figure either way.

Additive Antiplatelet Effect and Bleeding Risk

Two flavonoids isolated from Leuzea carthamoides, eriodictyol and patuletin, inhibited human platelet aggregation in laboratory assays, and the whole ethanol extract inhibited collagen- and adenosine-diphosphate-induced aggregation (Koleckar et al., 2008). This matters mainly alongside blood-thinning drugs or before surgery.

Magnitude: Direction is inhibitory at laboratory concentrations, with activity lost once the flavonoids are glycosylated; no human bleeding-outcome figure has been reported.

Gastrointestinal Intolerance

Trials of purified 20-hydroxyecdysone report only mild-to-moderate adverse events, gastrointestinal complaints among the most common, and rates did not exceed placebo (Fielding et al., 2025). Crude root powder adds bitter sesquiterpene lactones, more often linked to nausea than the purified compound.

Magnitude: Treatment-related adverse events occurred in 13.5% on the higher dose and 13.3% on the lower dose versus 16.0% on placebo over six to nine months of continuous use.

Speculative 🟨

Estrogen Receptor Beta Activation in Hormone-Sensitive Tissue

Because ecdysterone transactivates estrogen receptors in transfected cells (Parr et al., 2014), a theoretical concern exists for estrogen-sensitive tumours. No clinical case has been reported, and laboratory breast-cancer work shows growth inhibition rather than stimulation.

Embryotoxicity Signal in Pregnancy and Lactation

20-Hydroxyecdysone and polypodine B from the root were embryotoxic in an early laboratory screen (Kosar et al., 1997). No human pregnancy or lactation data exist, so the basis is that single report.

Photosensitivity from Root Polyacetylenes

A thiophene polyacetylene isolated from the roots showed phototoxic activity comparable to a standard photosensitiser in laboratory and invertebrate assays (Chobot et al., 2006). No human photosensitivity has been reported.

Risk-Modifying Factors

• Genetic polymorphisms: No pharmacogenetic variant has been mapped for ecdysteroid handling. Because clearance is largely renal rather than cytochrome-mediated, variants in drug-metabolising enzymes are unlikely to be the dominant source of variation.

• Baseline biomarker levels: Baseline platelet count, international normalised ratio (INR, a clotting-time index) and resting blood pressure determine whether the antiplatelet and stimulant concerns are theoretical or actionable for a given individual.

• Sex-based differences: Safety data in women are effectively absent outside the sarcopenia trial, which was 54% female (Fielding et al., 2025). Because the proposed mechanism runs through an estrogen receptor, women carry more of the unquantified uncertainty.

• Pre-existing health conditions: Uncontrolled hypertension, epilepsy, insomnia, cardiac arrhythmia and any estrogen-sensitive cancer shift this from a low-risk to an unquantified-risk intervention, since none has been studied and all appear in traditional contraindication lists.

• Age-related considerations: Reduced kidney function with age slows renal clearance of 20-hydroxyecdysone. Older users are also more likely to take blood thinners and antihypertensives, which is where the plausible interactions sit.

Key Interactions & Contraindications

• Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, low-dose aspirin): Caution. Additive platelet inhibition from the root’s flavonoids could raise bruising and bleeding risk. Mitigation: avoiding the combination, or checking INR and platelet function before and four weeks after starting.

• Antihypertensives (lisinopril, amlodipine, bisoprolol): Caution. Direction of the blood-pressure effect is unresolved, so either loss of control or additive lowering is possible. Mitigation: home blood-pressure logging twice weekly for the first month.

• Over-the-counter analgesics (ibuprofen, naproxen, aspirin): Caution. Non-steroidal anti-inflammatory drugs already impair platelet function; adding an antiplatelet botanical compounds that effect. Mitigation: separated use, and cessation 7–10 days before any planned procedure.

• Over-the-counter stimulants and decongestants (pseudoephedrine, high-dose caffeine): Caution. Additive central stimulation may cause insomnia, restlessness and palpitations. Mitigation: total caffeine held under 200 mg on dosing days, and no decongestant in the evening.

• Supplement interactions — antiplatelet botanicals (ginkgo, garlic extract, high-dose fish oil, curcumin, nattokinase): Caution. These share the platelet-inhibition mechanism, so the additive effect is the concern, not any novel one. Mitigation: only one such agent at a time around surgery or dental work.

• Supplement interactions — stimulant adaptogens (Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng): Caution. Marketed blends stack these deliberately; the human blend trial showed no added benefit, so the stack adds stimulation without demonstrated gain. Mitigation: separate dosing of the components first.

• Supplements with additive effects worth naming (creatine monohydrate, whey protein, leucine): No interaction risk identified. These act on the same endpoint — muscle protein synthesis — through independent routes; the practical issue is attributing any observed gain to the wrong agent.

• Other intervention interactions: Caution. Resistance training is required for the muscle claim to be testable. Aggressive caloric restriction or a glucagon-like peptide-1 agonist (GLP-1 agonist, the injected weight-loss drug class) blunts protein synthesis, the setting a current trial is probing.

Populations who should avoid Maral Root:

• Pregnant or breastfeeding women — an early laboratory screen found the root’s ecdysteroids embryotoxic, and no human data exist.
• Anyone with an estrogen-sensitive cancer (breast, endometrial, ovarian) — the proposed mechanism is estrogen-receptor activation.
• Athletes in national or international testing pools — the compound is on the World Anti-Doping Agency Monitoring Program and its status may change.
• Uncontrolled hypertension (resting blood pressure above 160/100 mmHg) or a seizure disorder — both are long-standing contraindications in Russian practice.
• Anyone on therapeutic anticoagulation or within 10 days of planned surgery — additive antiplatelet effect.
• Advanced kidney impairment (estimated glomerular filtration rate below 30 mL/min/1.73 m²) — clearance is predominantly renal.

Risk Mitigation Strategies

• Third-party-certified product only: A batch carrying NSF Certified for Sport, Informed Sport or USP verification is the single measure that addresses both label under-dosing and undeclared prohibited drugs, the two highest-evidence risks here.

• Certificate of analysis with quantified 20-hydroxyecdysone: A supplier-issued chromatographic assay stating milligrams per serving prevents paying for an inert powder; a certificate reporting only “extract weight” or a plant-part identity test does not.

• Morning dosing: A full dose taken before noon prevents the central-stimulation risk from expressing as insomnia and agitation, given the 2.4–4.9-hour half-life and the traditional contraindication in sleep disorders.

• Cessation 10 days before surgery or dental extraction: This clears the antiplatelet flavonoids well beyond their elimination window and removes the additive bleeding risk identified in platelet-aggregation work.

• Four weeks of home blood-pressure logging: Twice-weekly seated readings catch either direction of the unresolved blood-pressure effect early, before it becomes clinically relevant in someone already treated for hypertension.

• Single-ingredient products over “natural anabolic” blends: Single-ingredient products remove the contamination and undeclared-stimulant risk concentrated in proprietary blends, and make any observed effect attributable.

• Disclosure to a treating clinician: Disclosure prevents an unexplained bleeding time or blood-pressure change being attributed to prescription therapy, and is the practical control for interactions that have never been formally studied.

Therapeutic Protocol

• Standard extract protocol: The common practitioner approach is a root extract standardised to 5–10% 20-hydroxyecdysone, 200–500 mg of extract daily, supplying roughly 10–50 mg of 20-hydroxyecdysone, taken continuously alongside resistance training.

• Isolated-compound protocol: The alternative uses purified 20-hydroxyecdysone rather than extract. The training study that produced the positive human signal used a labelled 200–800 mg daily, though product analysis suggests actual intake was far lower.

• Pharmaceutical approach: Biophytis, which owns the compound commercially, used 175–350 mg of purified 20-hydroxyecdysone twice daily in older adults — an order of magnitude above supplement practice, and a genuinely different paradigm rather than a dose refinement.

• Adaptogen-school approach: The Brekhman and Dardymov tradition that popularised leuzea used low-dose alcoholic tincture cycled over 2–3 weeks for fatigue and convalescence, not continuous high-dose extract for hypertrophy. Neither approach is established as the default.

• Best time of day: Morning, before or shortly after training. This aligns peak exposure with the training stimulus and keeps the compound’s stimulant character away from the sleep window.

• Half-life: Human dosing gives a plasma half-life of 2.4–4.9 hours, with a modest 1.31-fold accumulation over 14 days of twice-daily dosing (Dioh et al., 2023) — short enough that once-daily coverage is partial.

• Single versus split dosing: The short half-life argues for splitting: the pharmaceutical programme used twice-daily dosing, while supplement practice is usually a single morning dose. No head-to-head comparison of schedules exists.

• Genetic polymorphisms: No variant is validated here. ESR2 is the plausible candidate; CYP2D6 (a liver drug-clearing enzyme), MTHFR (folate processing) and COMT (breaks down dopamine) should not matter, since clearance is renal.

• Sex-based differences: All dosing precedent in trained populations comes from men. Women have no established dose; the conservative approach is the lower end of the extract range with the same monitoring.

• Age-related considerations: Adults over 65 showed 13–22% lower plasma exposure than young adults on identical doses (Dioh et al., 2023), which is one argument for the higher end of the range in that group, tempered by reduced renal clearance.

• Baseline biomarker levels: Fasting glucose, triglycerides and an inflammatory marker define whether the metabolic claims are even testable in a given person; near-optimal values leave no measurable room for change.

• Pre-existing health conditions: Sarcopenia, obesity and impaired glucose tolerance are the states with the largest reported signals. Uncontrolled hypertension, seizure disorder and estrogen-sensitive cancer are the states in which no protocol applies.

Discontinuation & Cycling

• Intended duration: Not established as lifelong. Every controlled human exposure has run 8–12 weeks, with the pharmaceutical programme reaching nine months; nothing supports or refutes indefinite use.

• Withdrawal effects: None reported. No trial has described rebound fatigue, mood change or strength loss beyond the expected detraining seen when any training-linked aid is removed.

• Tapering: Not applicable. With a half-life under five hours and no receptor-downregulation signal, abrupt cessation carries no described consequence and no tapering schedule has been proposed.

• Cycling for efficacy: The traditional adaptogen school cycles 2–3 weeks on and 1–2 weeks off; the pharmaceutical programme dosed continuously for months. No tolerance mechanism is documented, so cycling rests on tradition rather than data.

• Practical stopping points: Discontinuation before surgery, before entering a drug-tested competition window, or after a 12-week block that produced no measurable change in body composition or strength are the defensible stopping triggers.

Sourcing and Quality

• Species identity: A reliable product states Rhaponticum carthamoides. Related species sold as “leuzea” or “rhaponticum” — including Rhaponticum uniflorum and rhubarb-derived Rheum rhaponticum — have different chemistry and are a common substitution.

• Plant part: Only root and rhizome are relevant; ecdysteroid content is concentrated there. Aerial-part or whole-herb material carries a different and generally lower phytoecdysteroid load, which is why plant part must be declared.

• Standardisation to 20-hydroxyecdysone: The informative marker is a stated percentage, typically 5–10%, verified by high-performance liquid chromatography or liquid chromatography–tandem mass spectrometry (LC-MS/MS). Native root runs 0.05–1.74%, so any “high-potency” claim without an assay is unsupported.

• Third-party certification: NSF Certified for Sport, Informed Sport and USP verification are the marks that address the documented mislabelling and contamination problems. Very few products in this category carry any of them.

• Identifiable named sources: Bulgarian producer VemoHerb supplies Rhaponticum-derived ecdysterone with published assays, and Biophytis produces pharmaceutical-grade material at 97% purity — the latter is not available as a supplement.

• Formulation: Alcoholic tincture reflects traditional preparation; standardised dry extract in capsules is the form used in every quantified study. Raw root powder cannot deliver a controlled ecdysteroid dose.

• Manufacturing controls: Current Good Manufacturing Practice (GMP, the audited production standard for supplements) certification plus heavy-metal and microbial testing matter here, since Siberian and Chinese wild-harvested roots carry soil-contaminant risk.

Practical Considerations

• Time to effect: The training studies measured change at 4, 8 and 10–12 weeks; the earliest separation from placebo appeared around 8 weeks. Nothing supports an acute or within-days effect.

• Common pitfall — no training stimulus: The proposed mechanism acts on muscle that is already being loaded. Taking it without progressive resistance training removes the only context in which a benefit has ever been reported.

• Common pitfall — trusting the label: Because content is routinely far below claim, an apparent personal non-response is at least as likely to reflect an inert product as a real absence of effect.

• Common pitfall — stacking blends: Multi-ingredient “natural anabolic” products make attribution impossible and concentrate the contamination risk documented in this supplement category.

• Regulatory status: Sold as a dietary supplement in the United States and European Union with no pre-market efficacy review. Purified 20-hydroxyecdysone is an investigational drug, not approved anywhere. Ecdysterone is monitored, not prohibited, in sport.

• Structural funding bias: No insurer or health system pays for either form, so neither has a payer with an incentive to fund comparative trials. The only party financing rigorous work is developing a patented purified version, which directs research toward the isolate.

• Cost and accessibility: Standardised extract runs roughly USD 20–40 per month, so cost is not a barrier. Genuinely assayed, certified product is the scarce item, not the raw material.

Interaction with Foundational Habits

• Sleep: Potentially blunting, and indirect. Central nervous system stimulation shown in rodents plus the traditional insomnia contraindication make late dosing the plausible route to disrupted sleep onset. Practical step: a full dose before noon, not combined with evening caffeine or stimulant pre-workout formulas.

• Nutrition: Potentiating, and indirect. The proposed effect runs through muscle protein synthesis, which is substrate-limited, so adequate protein — roughly 1.6–2.2 g/kg daily — is the enabling condition. The compound depletes no known nutrient; food does not obviously alter its absorption.

• Exercise: Potentiating, and direct. Every positive human result came from participants doing structured resistance training three times weekly; the compound did nothing measurable without it. Practical step: morning dosing on training days, positioned as an add-on to progressive overload rather than a substitute for it.

• Stress management: Blunting, and indirect. The adaptogen framing implies a damped stress-hormone response, and rodent work shows restored corticosterone after high-fat-diet stress, but the one human blend trial found no change in mood or arousal. No timing or technique interaction is established.

Monitoring Protocol & Defining Success

Because no regulator requires safety monitoring for maral root, the sensible monitoring plan is borrowed from what the trials of its purified constituent actually measured. A baseline drawn one to two weeks before starting covers liver enzymes, kidney function, a fasting metabolic panel, an inflammatory marker, a lipid panel and — for anyone using it for muscle — a sex-hormone panel and a body-composition scan, so that any later change has a reference point. Ongoing testing can be light, because no organ toxicity has been identified: repeat the liver and kidney panel at 6–8 weeks, then run the full set at 6 months and every 6–12 months thereafter if use continues. Body composition and strength testing repeat at 12 weeks, the shortest interval over which the training studies detected change.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)	ALT 10–26 U/L; AST 10–26 U/L	Detects liver stress from an unregulated botanical or an undeclared contaminant	ALT is alanine aminotransferase and AST aspartate aminotransferase, both liver enzymes. Conventional labs flag only above 40–55 U/L; draw fasted and at least 48 h after hard training
Estimated glomerular filtration rate (eGFR) and creatinine	eGFR above 90 mL/min/1.73 m²	Clearance is predominantly renal, so kidney function sets exposure	eGFR estimates how fast the kidneys filter blood. Conventional labs flag only below 60 mL/min/1.73 m². Creatinine rises with muscle mass and creatine use; pair with cystatin C if lean mass is high
Fasting glucose	75–86 mg/dL	Tracks the metabolic claim seen in animal work	Conventional reference range runs to 99 mg/dL. Requires 10–12 h fast; a single reading is noisy, so pair with HbA1c (three-month average blood sugar)
Haemoglobin A1c (HbA1c)	4.8–5.3%	Three-month average glucose; the stable counterpart to a fasting reading	HbA1c is glycated haemoglobin. Conventional labs flag only at 5.7% and above. Falsely low with short red-cell lifespan; no fasting needed
Fasting insulin	2–5 µIU/mL	The earliest marker to move if insulin sensitivity improves	Conventional reference range extends to about 25 µIU/mL. Must be drawn with fasting glucose to allow a combined index; morning draw preferred
High-sensitivity C-reactive protein (hs-CRP)	Below 0.5 mg/L	Tests the anti-inflammatory claim	hs-CRP is a general marker of body-wide inflammation. Conventional cardiac cut-off is 3.0 mg/L; postpone if unwell or within 72 h of hard training
Triglycerides and LDL cholesterol	Triglycerides below 80 mg/dL; LDL cholesterol below 100 mg/dL	Tests the lipid claim from the rodent metabolic work	LDL is low-density lipoprotein and HDL high-density lipoprotein, the cholesterol-carrying particles linked to higher and lower heart risk. Conventional cut-offs are far looser (triglycerides 150 mg/dL, LDL cholesterol 130 mg/dL). Requires 12 h fast for triglycerides; triglyceride-to-HDL ratio below 1.5 is the more informative derived figure
Total testosterone and estradiol	Men: testosterone 600–900 ng/dL, estradiol 20–30 pg/mL	Confirms the absence of the hormonal shift seen with anabolic steroids	Conventional male reference ranges are much wider (testosterone roughly 300–1000 ng/dL). Draw between 07:00 and 10:00; use a sensitive assay for estradiol. Trials found no change, so a shift points to an adulterated product
Insulin-like growth factor 1 (IGF-1)	Mid-to-upper half of the age-specific reference range	The one hormone that separated groups in the human training study	IGF-1 is a growth hormone-dependent anabolic signal. Age-dependent, so interpret against an age band, not a single number
Resting blood pressure	Below 120/80 mmHg	The one traditional contraindication with a plausible mechanism	Home cuff, seated, twice weekly for the first month; single clinic readings miss the drift this is meant to catch
Lean body mass (DXA)	No established target; track change from the individual’s own baseline	The primary endpoint the human evidence rests on	DXA is dual-energy X-ray absorptiometry, a body-composition scan. Bioelectrical impedance is too imprecise for a 1–2 kg change; keep hydration and timing constant

Qualitative markers worth tracking alongside the labs:

• Sleep onset latency and night waking, logged for the first two weeks, since central stimulation is the most likely early adverse signal.
• Session rating of perceived exertion at a fixed training load — the practical proxy for the fatigue-resistance claim.
• Training volume load (sets × reps × weight) per week, which is the honest test of whether anything changed.
• Subjective recovery between sessions and morning resting heart rate.
• Appetite and gastrointestinal comfort, the most commonly reported complaint in the trials.
• Success is defined narrowly: a measurable rise in lean mass or 1RM beyond normal training progression by week 12, with no drift in liver, kidney or blood-pressure markers.

Emerging Research

• Muscle preservation during drug-induced weight loss: Biophytis, the compound’s commercial owner, has registered a 164-participant Phase 2 trial (NCT07411378) of purified 20-hydroxyecdysone versus placebo in adults with obesity starting semaglutide, with knee-extension strength at 21 weeks as the primary endpoint.

• Completed sarcopenia trial: The 233-participant Phase 2 SARA-INT study (NCT03452488) used 400-metre gait speed as its primary endpoint. The pandemic cost 55% of end-of-treatment assessments, so its per-protocol result carries more weight than its power justifies.

• Antiparasitic application: A Phase 2/3 trial of 200 participants (NCT04827537) compares 20-hydroxyecdysone with metronidazole for Giardia infection, running to 2027 — a therapeutic direction entirely separate from the muscle and longevity claims.

• Prediabetes signal: A 34-participant study (NCT03906201) measured fasting glucose, HbA1c and micronucleus counts over 90 days. Registry status has been unknown since 2020, so this may be the rare human metabolic dataset that never appears.

• Evidence that could weaken the case: A 12-week randomised trial found no benefit from a commercial phytosteroid product and traced this to the product containing under 1% of its claimed content (Dissemond et al., 2025) — a template for re-testing every positive supplement result.

• Detection science: Mapping of more than 20 previously unknown human urinary metabolites (Piper & Thevis, 2023) removes the analytical obstacle to prohibiting ecdysterone in sport, which would change availability and price for everyone, not only athletes.

• Whole-extract longevity work: The nematode lifespan result (Todorova et al., 2025) is the first study to test the crude root rather than the isolate against an ageing endpoint, and is the obvious candidate for replication in a vertebrate model.

Conclusion

Maral root is the root of a Siberian mountain plant carrying an unusually rich mix of plant steroids and antioxidant compounds. Its reputation rests on a long Russian tradition of using it to restore strength and endurance, and on laboratory work showing that its main compound enlarges muscle fibres without acting on the same receptor as testosterone.

For adults who train seriously and track their own markers, the practical picture is narrow. One controlled training study found greater gains in muscle size and pressing strength than dummy treatment; another found nothing. Animal work is broader and fairly consistent for blood sugar, blood fats, blood-vessel inflammation and stress resistance, but almost none of it has been repeated in people, and no one has been followed for longer than a few months.

The most reliable finding in this field is not about the plant at all: products sold for their main active compound repeatedly contain far less than their labels claim, and sports supplements in this category sometimes carry undeclared drugs. Much of the strongest human data comes from a company developing a patented purified version of that compound, and from anti-doping laboratories that are funded to detect it and have argued for banning it — both have something at stake. The cheap crude root has no comparable sponsor, which is part of why it stays thinly studied. The case rests on plausible biology, deep traditional use, and a shallow human record.

Top - Benefits - Risks - Protocol